Vertex Pharmaceuticals Inc (NASDAQ:VRTX)
| 79.47 Data as of May 21 |  +2.09 / +2.70%Today’s Change | 38.44 Today|||52-Week Range 87.47 | +89.67% Year-to-Date |
Latest VRTX News | Press Releases
| 5 Stocks Underperforming Today In The Drugs Industry May 20 / TheStreet.com | 3 Stocks Underperforming Today In The Drugs Industry May 15 / TheStreet.com |
| Vertex Pharmaceuticals (VRTX): Today's Featured Health Care Laggard May 16 / TheStreet.com |
Today’s Trading
| Previous close | 77.38 |
| Today’s open | 77.61 |
| Day’s range | -- - -- |
| Volume | 1,722,364 |
| Average volume (3 months) | 2,534,410 |
| Market cap | $17.1B |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/21/2013
Growth & Valuation
| Earnings growth (last year) | -457.14% |
| Earnings growth (this year) | -244.17% |
| Earnings growth (next 5 years) | +19.00% |
| Revenue growth (last year) | +8.25% |
| P/E ratio | NM |
| Price/Sales | 5.82 |
| Price/Book | 16.83 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ACTActavis Inc | +3.05 | +2.40% |
| ZTSZoetis Inc | -0.67 | -1.99% |
| SHPGShire PLC | +1.66 | +1.74% |
| ALXNAlexion Pharmaceutic... | +2.64 | +2.64% |
Data as of 4:01pm ET, 05/21/2013
Financials
| Next reporting date | July 29, 2013 |
| EPS forecast (this quarter) | -$0.14 |
| Annual revenue (last year) | $1.5B |
| Annual profit (last year) | -$107.0M |
| Net profit margin | -7.01% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Jeff M. Leiden, PhD, MD |
Chief Financial Officer & Executive Vice President Ian F. Smith, CPA |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
